NextVivo
NextVivo is dedicated to developing immune organoid technology for drug development, aiming to create safer, more effective therapies using immune competent human-derived models. Their innovative 3D organoids retain key immune cell types and their interactions, enabling applications in cancer, infections, autoimmune diseases, and personalized medicine. They focus on generating antibody and cellular therapies, preclinical drug testing, and precision diagnostics to improve drug efficacy and safety.
Industries
Nr. of Employees
small (1-50)
Products
Immune-competent organoid platform
A laboratory platform for generating and maintaining 3D human tissue organoids at an air-liquid interface that preserve endogenous immune cell populations and tissue architecture for discovery, testing, and diagnostic uses.
Immune-competent organoid platform
A laboratory platform for generating and maintaining 3D human tissue organoids at an air-liquid interface that preserve endogenous immune cell populations and tissue architecture for discovery, testing, and diagnostic uses.
Services
Laboratory service to generate and characterize human antibodies using in vitro lymphoid tissue models that recapitulate adaptive immune processes.
Service to derive and optimize cellular therapies from a patient’s immune cells using patient-matched tumor organoids to select effectors that recognize tumor-specific antigens.
Assay and screening services that test drug candidates on immune-competent human organoids to evaluate efficacy and immune-related adverse effects prior to clinical studies.
Functional diagnostic testing that evaluates multiple approved or experimental therapies on a patient’s disease tissue in organoid culture to inform individualized treatment choices.
Laboratory service to generate and characterize human antibodies using in vitro lymphoid tissue models that recapitulate adaptive immune processes.
Service to derive and optimize cellular therapies from a patient’s immune cells using patient-matched tumor organoids to select effectors that recognize tumor-specific antigens.
Assay and screening services that test drug candidates on immune-competent human organoids to evaluate efficacy and immune-related adverse effects prior to clinical studies.
Functional diagnostic testing that evaluates multiple approved or experimental therapies on a patient’s disease tissue in organoid culture to inform individualized treatment choices.
Expertise Areas
- Organoid culture using air-liquid interface
- Immune-oncology modeling and tumor microenvironment
- In vitro antibody discovery from human lymphoid tissue
- Personalized cell therapy generation
Key Technologies
- Air-liquid interface organoid culture
- Immune-competent 3D organoids
- Germinal center modeling in vitro
- Ex vivo patient-derived tumor organoids